Polaris Quantum Biotech (PolarisQB) has announced the official launch of QuADD (Quantum-Aided Drug Design), a SaaS platform for drug discovery that uses quantum computing and artificial intelligence. The platform is designed to solve combinatorial library optimization problems, with the aim of accelerating drug candidate identification timelines. PolarisQB is inviting researchers, biotech companies, and academic teams to join a beta program to gain early access to the platform.
QuADD harnesses quantum annealers, a technology from PolarisQB’s partnership with D-Wave, to explore a chemical space of up to 10³⁰ theoretical molecules. The technology is designed to optimize for drug-like criteria such as blood-brain barrier permeability, solubility, toxicity, metabolic stability, and geometric fit. It also scores binding energy, functional groups, and orientation to maximize molecular efficacy. The platform delivers libraries of 1,000–10,000 molecules for downstream computational or experimental evaluation. QuADD is deployed as a secure and isolated SaaS platform accessible globally, and it provides capabilities for scaffold-hopping and IP-periphery exploration.
By using quantum annealing, QuADD aims to accelerate the drug candidate identification timeline. The technology is intended to enable researchers to focus their experiments on what it identifies as promising, synthesizable molecules. The beta program is designed to provide participants with early access and an opportunity to contribute to the platform’s development. PolarisQB’s platform is applicable to any protein target and can be used for both de novo combinatorial spaces and on-demand chemical libraries.
Read the full announcement from Polaris Quantum Biotech here, learn more about the QuADD platform here, and review QCR’s previous report on their partnership with Scientist.com here.
August 12, 2025
